Cost-effectiveness of a collaborative care program for primary care patients with persistent depression

American Journal of Psychiatry

Volumn 158, Issue 10, 2001, Pages 1638-1644

  Simon, G E ^a   Katon, W J ^a   VonKorff, M ^a   Unutzer J ^a   Lin, E H B ^a   Walker, E A ^a   Bush, T ^a   Rutter, C ^a   Ludman, E ^a  

^a CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH CARE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RESOURCE ALLOCATION; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; CONTINUITY OF PATIENT CARE; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH SERVICES; HUMANS; MALE; MANAGED CARE PROGRAMS; PATIENT CARE TEAM; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIMARY HEALTH CARE; PSYCHIATRY; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 0034814449     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.10.1638     Document Type: Article

References (37)

1. Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 study
2. The functioning and well-being of depressed patients: Results from the medical outcomes study
3. Common mental disorders and disability across cultures
4. Health-related quality of life in primary care patients with mental disorders
5. The "usual care" of major depression in primary care practice
6. Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the medical outcomes study
7. Medication management of depression in the United States and Canada
8. Treating major depression in primary care practice: Eight-month clinical outcomes
9. Randomized trial of a depression management program in high utilizers of medical care
10. Collaborative management to achieve treatment guidelines: Impact on depression in primary care
11. A multifaceted intervention to improve treatment of depression in primary care
12. Stepped collaborative care for primary care patients with persistent symptoms of depression: A randomized trial
13. Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care
14. Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial
15. Cost-effectiveness of treatments for major depression in primary care practice
16. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care
17. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression
18. The Hopkins symptom checklist (HSCL): A measure of primary symptom dimensions
19. A chronic disease score from automated pharmacy data
20. A chronic disease score with empirically derived weights
21. Social consequences of psychiatric disorders, I: Educational attainment
22. Lost human capital from early-onset chronic depression
23. The social consequences of psychiatric disorders, III: Probability of marital stability
24. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices
25. Quality adjusted life years in older adults with depressive symptoms and chronic medical disorders
26. Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications
27. Health-related quality of life in mental health services evaluation
28. The beaver dam health outcomes study: Initial catalog of health state quality factors
29. Preliminary longitudinal assessment of quality of life in patient with major depression
30. Five-hundred life-saving interventions and their cost-effectiveness
31. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction
32. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease